Tianjin Chase Sun Pharmaceutical Co.,Ltd (SHE:300026)

China flag China · Delayed Price · Currency is CNY
3.170
+0.070 (2.26%)
Jul 3, 2026, 3:04 PM CST
Market Cap9.52B -17.7%
Revenue (ttm)4.68B -18.1%
Net Income23.88M +0.9%
EPS0.01 +14.4%
Shares Out 3.00B
PE Ratio254.45
Forward PEn/a
Dividend0.01 (0.32%)
Ex-Dividend DateJun 24, 2025
Volume60,124,928
Open2.990
Previous Close3.100
Day's Range2.990 - 3.180
52-Week Range2.820 - 4.490
Beta0.06
Analystsn/a
Price Targetn/a
Earnings DateAug 26, 2026

About SHE:300026

Tianjin Chase Sun Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of various pharmaceutical products in China. The company offers traditional Chinese medicine formula granules; finished drugs, including xuebijing injections, low molecular weight heparin calcium injections, moxifloxacin hydrochloride sodium chloride injections, enoxaparin sodium injections, nadronexacin calcium injections, fasudil hydrochloride injections, ketorheic acid tromethamine injections, ibanoxetine sodium injections, Qingfei Sanjie pi... [Read more]

Sector Healthcare
Founded 1996
Employees 4,852
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300026
Full Company Profile

Financial Performance

In 2025, SHE:300026's revenue was 4.94 billion, a decrease of -14.55% compared to the previous year's 5.78 billion. Earnings were 18.50 million, a decrease of -13.85%.

Financial Statements